Recent submissions
Now showing items 41-60 of 4783
-
A Functional Survey of the Regulatory Landscape of Estrogen Receptor-Positive Breast Cancer Evolution.
(AMER ASSOC CANCER RESEARCH, 2024-09-04)Only a handful of somatic alterations have been linked to endocrine therapy resistance in hormone-dependent breast cancer, potentially explaining ∼40% of relapses. If other mechanisms underlie the evolution of hormone-dependent ... -
Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.
(ELSEVIER, 2024-07-01)Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. ... -
Developing whole-body MRI methods for assessing heterogeneity and response to immunotherapy in patients with metastatic melanoma
(Institute of Cancer Research (University Of London), 2024-08-13)Conventional response criteria are failing to accurately reflect which patients with metastatic melanoma (MM) are benefiting from treatment with immune checkpoint inhibitors (ICPI). The aim of this work was to develop ... -
Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023.
(ELSEVIER, 2024-07-01)BACKGROUND: In a competitive landscape with many ongoing adjuvant randomised controlled trials (RCTs), the prevalence of trials that failed to recruit their targeted sample size and were inadequately powered is unclear. ... -
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
(NATURE PORTFOLIO, 2024-06-29)Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression ... -
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study.
(ELSEVIER IRELAND LTD, 2024-05-01)BACKGROUND AND PURPOSE: MRI-guided radiotherapy (MRIgRT) offers multiple potential advantages over CT-guidance. This study examines the potential clinical benefits of MRIgRT for men with localised prostate cancer, in the ... -
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.
(ELSEVIER, 2023-07-01)BACKGROUND: Recurrence of non-muscle-invasive bladder cancer (NMIBC) is common after transurethral resection of bladder tumour (TURBT). Photodynamic diagnosis (PDD) may reduce recurrence. PDD uses a photosensitiser in the ... -
Impact of on-trial IGRT quality assurance in an international adaptive radiotherapy trial for participants with bladder cancer.
(ELSEVIER IRELAND LTD, 2024-07-26)BACKGROUND AND PURPOSE: Radiotherapy trial quality assurance (RT QA) is crucial for ensuring the safe and reliable delivery of radiotherapy trials, and minimizing inter-institutional variations. While previous studies ... -
U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes.
(ELSEVIER, 2024-07-01)BACKGROUND: Determining the maximum tolerated dose (MTD) remains the primary objective for the majority of dose-finding oncology trials. Whilst MTD determination often relies upon clinicians to identify dose-limiting ... -
Deciphering the genetics and mechanisms of predisposition to multiple myeloma.
(NATURE PORTFOLIO, 2024-08-05)Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study ... -
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
(American Society for Clinical Investigation, 2024-06-04)BACKGROUND: Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The ... -
Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs.
(Springer Science and Business Media LLC, 2024-06-19)BACKGROUND: In light of the FDA's Project Optimus initiative, there is fresh interest in leveraging Patient-reported Outcome (PRO) data to enhance the assessment of tolerability for investigational therapies within early ... -
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
(ELSEVIER SCI LTD, 2024-07-01)BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor ... -
Nuclear rupture induced by capillary constriction forces promotes differential effects on metastatic and normal breast cells.
(NATURE PORTFOLIO, 2024-06-26)During metastatic dissemination, circulating tumour cells (CTCs) enter capillary beds, where they experience mechanical constriction forces. The transient and persistent effects of these forces on CTCs behaviour remain ... -
The genomic landscape of 2,023 colorectal cancers.
(Springer Science and Business Media LLC, 2024-09-05)Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK ... -
Exploring the role of stereotactic body radiotherapy to sites of oligoprogression to improve outcomes
(Institute of Cancer Research (University Of London), 2024-08-09)mproved treatments for metastatic non-small cell lung cancer (NSCLC) and prostate cancer has unearthed a clinical state called oligoprogressive disease (OPD). OPD is poorly defined, broadly speaking it features progression ... -
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.
(WILEY, 2024-09-01)Pembrolizumab has received approval in the UK as first-line monotherapy for recurrent and/or metastatic HNSCC (R/M HNSCC) following the results of the KEYNOTE-048 trial, which demonstrated a longer overall survival (OS) ... -
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
(ELSEVIER, 2024-05-01)BACKGROUND: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, ... -
OSIPI: A Significant Step Towards Reproducible MR Biomarkers.
(WILEY, 2024-04-27) -
NTRK gene fusion testing and management in lung cancer.
(ELSEVIER SCI LTD, 2024-06-01)Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed ...